OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
May 16, 2022
Plan to keep new methods adopted during COVID in place.
May 06, 2022
Access to mifepristone, approved by the agency in 2000, also under microscope.
May 04, 2022
Medical device user-fees agreement, Aduhelm approval and access among issues in crosshairs.
April 26, 2022
As regulatory reform continues, a more personalized treatment landscape is on the horizon.
April 20, 2022
Dual efforts focused on more inclusive research and more diverse enrollment in pre- and post-approval studies.
April 18, 2022
Transition likely with looming end to emergency use authorizations tied to COVID-19 pandemic.
April 13, 2022
Program looks to establish framework for agency and purchasers to “objectively rate” manufacturing sites.
April 12, 2022
Congressional bills put focus on comparator-drug access, more accurate trial and R&D cost determinations.
April 11, 2022
Fresh round of discussions around health technology assessment.
April 07, 2022
Several legislative initiatives on table that would extend agency’s reach.